Parasympathetic control of cardiac sympathetic activity: Normal ventricular function versus congestive heart failure

Circulation

Volumn 100, Issue 3, 1999, Pages 274-279

  Azevedo, Eduardo R ^b   Parker, John D ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

^b NONE

Author keywords

Acetylcholine; Nervous system, autonomic; Norepinephrine; Receptors

Indexed keywords

ATROPINE; CATECHOLAMINE; MUSCARINIC RECEPTOR; NORADRENALIN;

ADRENERGIC NERVE; ADULT; ARTICLE; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; FEMALE; HEART LEFT VENTRICLE FUNCTION; HEMODYNAMIC MONITORING; HUMAN; MALE; NERVE ENDING; NORADRENALIN RELEASE; PARASYMPATHETIC INNERVATION; PRIORITY JOURNAL; RECEPTOR BLOCKING; REGULATORY MECHANISM; SYMPATHETIC TONE;

EID: 0033587668     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.100.3.274     Document Type: Article

References (37)

1. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984; 311:819-823.
2. Kaye DM, Lefkovits J, Jennings GL, Bergin P, Broughton A, Esler MD. Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol. 1995;26:1257-1263.
3. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, Gilbert EM, Johnson MR, Goss FG, Hjalmarson A. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet. 1993;342: 1441-1446.
4. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U. S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334:1349-1355.
5. Eckberg DL, Drabinsky M, Braunwald E. Defective cardiac parasympathetic control in patients with heart disease. N Engl J Med. 1971;285: 877-883.
6. Porter TR, Eckberg DL, Fritsch JM, Rea RF, Beightol LA, Schmedtje JFJ, Mohanty PK. Autonomie pathophysiology in heart failure patients. Sympathetic-cholinergic interrelations. J Clin Invest. 1990;85: 1362-1371.
7. Löffelholz K, Muscholl E. A muscarinic inhibition of the noradrenaline release evoked by postganglionic sympathetic nerve stimulation. Naunyn Schmiedebergs Arch Pharmacol. 1969;265:1-15.
8. Vanhoutte PM. Inhibition by acetylcholine of adrenergic neurotransmission in vascular smooth muscle. Circ Res. 1974;34:317-326.
9. Löffelholz K. Release of acetylcholine in the isolated heart. Am J Physiol. 1981;240:H431-H440.
10. Casado MA, Sevilla MA, Alonso MJ, Marin J, Salaices M. Muscarinic receptors involved in modulation of norepinephrine release and vasodilatation in guinea pig carotid arteries. J Pharmacol Exp Ther. 1994;271: 1638-1646.
11. Jumblatt JE, Hackmiller RC. M2-type muscarinic receptors mediate prejunctional inhibition of norepinephrine release in the human irisciliary body. Exp Eye Res. 1994;58:175-180.
12. Matko I, Feher E, Vizi ES. Receptor mediated presynaptic modulation of the release of noradrenaline in human papillary muscle. Cardiovasc Res. 1994;28:700-704.
13. Kaye DM, Lambert GW, Lefkovits J, Morris M, Jennings G, Esler MD. Neurochemical evidence of cardiac sympathetic activation and increased central nervous system norepinephrine turnover in severe congestive heart failure. J Am Coll Cardiol. 1994;23:570-578.
14. Ganz W, Tamura K, Marcus HS, Donoso R, Swan HJC. Measurement of coronary sinus blood flow by continuous thermodilution in man. Circulation. 1971;44:181-195.
15. Newton GE, Tong JS, Schofield AM, Baines AD, Floras JS, Parker JD. Digoxin reduces cardiac sympathetic activity in severe congestive heart failure, J Am Coll Cardiol. 1996;28:155-161.
16. Newton GE, Parker JD. Acute effects of beta1-selective and nonselective beta-adrenergic receptor blockade on cardiac sympathetic activity in congestive heart failure. Circulation. 1996;94:353-358.
17. Esler M, Jackman G, Bobik A, Kelleher D, Jennings G, Leonard P, Skews H, Korner P. Determination of norepinephrine apparent release rate and clearance in humans. Life Sci. 1979;25:1461-1470.
18. Newton GE, Parker AB, Landzberg JS, Colucci WS, Parker JD. Muscarinic receptor modulation of basal and beta-adrenergic stimulated function of the failing human left ventricle. J Clin Invest. 1996;98:2756-2763.
19. Benet LZ, Øie S, Schwartz JB. Design and optimization of dosage regimens; pharmacokinetics data. In: Hardman JG, Goodman Gilman A, Limbird LE, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw-Hill;1996:1707-1792.
20. Armour JA. Peripheral autonomic neuronal interactions in cardiac regulation. In: Armour JA, Ardell JL, eds. Neurocardiology. New York: Oxford University Press; 1994:219-244.
21. 2-muscarinic receptors increase in the canine pacing-overdrive model of heart failure. Can J Cardiol. 1996;11:71-76.
22. Huang MH, Smith FM, Armour JA. Modulation of in situ canine intrinsic cardiac neuronal activity by nicotinic, muscarinic, and b-adrenergic agonists. Am J Physiol. 1993;265:R659-R669.
23. Brodde OE, Konschak U, Becker K, Rüter F, Poller U, Jakubetz J, Radke J, Zerkowski HR. Cardiac muscarinic receptors decrease with age. In vitro and in vivo studies. J Clin Invest. 1998;101:471-478.
24. Caulfield MP, Birdsall NJ. International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev. 1998;50:279-290.
25. Levy MN. Sympathetic-parasympathetic interactions in the heart. Circ Res. 1971;29:437-445.
26. Levy MN, Blattberg B. Effect of vagal stimulation on the overflow of norepinephrine into the coronary sinus during cardiac sympathetic nerve stimulation in the dog. Circ Res. 1976;38:81-84.
27. Rardon DP, Bailey JC. Parasympathetic effects on electrophysiologic properties of cardiac ventricular tissue. J Am Coll Cardiol. 1983;2: 1200-1209.
28. Warner HR, Russell ROJ. Effect of combined sympathetic and vagal stimulation on heart rate in the dog. Circ Res. 1969;24:567-573.
29. Goldstein DS, Keiser HR. Pressor and depressor responses after cholinergic blockade in humans. Am Heart J. 1984;107:974-979.
30. Montano N, Cogliati C, Porta A, Pagani M, Malliani A, Narkiewicz K, Abboud FM, Birkett C, Somers VK. Central vagotonic effects of atropine modulate spectral oscillations of sympathetic nerve activity. Circulation. 1998;98:1394-1399.
31. Cook LS, Elkins RC, Doherty JE. Cardiovascular effects of atropine in postoperative cardiac patients receiving digoxin for ventricular dysfunction. Am Heart J. 1986;111:80-84.
32. Chamberlain DA, Turner P, Sneddon JM. Effects of atropine on heart-rate in healthy man. Lancet. 1967;2:12-15.
33. Harris WS, Schoenfeld CD, Weissler AM. Effects of adrenergic receptor activation and blockade on the systolic preejection period, heart rate, and arterial pressure in man. J Clin Invest. 1967;46:1704-1714.
34. Yamaguchi N, De Champlain J, Nadeau R. Correlation between the response of the heart to sympathetic stimulation and the release of endogenous catecholamines into the coronary sinus of the dog. Circ Res. 1975;36:662-668.
35. Rundqvist B, Eisenhofer G, Elam M, Friberg P. Attenuated cardiac sympathetic responsiveness during dynamic exercise in patients with heart failure. Circulation. 1997;95:940-945.
36. La Rovere MT, Mortara A, Pantaleo P, Maestri R, Cobelli F, Tavazzi L. Scopolamine improves autonomic balance in advanced congestive heart failure. Circulation. 1994;90:838-843.
37. Waxman MB. Wald RW. Termination of ventricular tachycardia by an increase in cardiac vagal drive. Circulation. 1977;56:385-391.